
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated robust financial performance, with sales increasing by 40% in 3Q25 compared to the same quarter in the previous year, driven by strong gains in key products such as Repatha and Tezspire. Additionally, management's guidance indicates an R&D growth of over 20% for 2025, which underscores the company's commitment to expanding its innovative pipeline and enhancing its market position. The raise in FY25 revenue guidance from $35.0-$36.0 billion to $35.8-$36.6 billion reflects the firm’s sustained strength across its established drug franchises and the positive impact of recent acquisitions.
Bears say
The analysis highlights a concerning outlook for Amgen as total revenue is projected to grow by only approximately 1% from 2025 to 2026, primarily due to significant expected sales declines for critical products such as Prolia and Xgeva, estimated at about 28% and 39%, respectively. Additionally, the company's research and development expenditures are anticipated to grow at a slower rate which could hinder the pipeline's ability to compensate for the erosion of its established product franchises due to impending losses of exclusivity. Despite Amgen's current position as a high-quality, defensive large-cap biotech company with stable near-term cash flows, the lack of long-term growth drivers raises concerns about its sustainability amidst structural challenges.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares